SEARCH

SEARCH BY CITATION

Keywords:

  • Talipexole;
  • Tourette's syndrome

Abstract

Talipexole is a new dopamine autoagonist with putative preferential activity on presynaptic dopamine receptors. In a double-blind, placebocontrolled study, we tested the drug's safety and efficacy in 13 adult men with Gilles de la Tourette's syndrome. The drug was poorly tolerated because of clinically significant sedation and dizziness. Tics did not improve at tolerable doses. These findings suggest that talipexole has no role in the regular management of tic disorders.